Key Laboratory of Pathobiology, Department of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, China.
Int J Mol Sci. 2023 Aug 2;24(15):12347. doi: 10.3390/ijms241512347.
Cisplatin is a first-line clinical agent used for treating solid tumors. Cisplatin damages the DNA of tumor cells and induces the production of high levels of reactive oxygen species to achieve tumor killing. Tumor cells have evolved several ways to tolerate this damage. Extracellular vesicles (EVs) are an important mode of information transfer in tumor cells. EVs can be substantially activated under cisplatin treatment and mediate different responses of tumor cells under cisplatin treatment depending on their different cargoes. However, the mechanism of action of tumor-cell-derived EVs under cisplatin treatment and their potential cargoes are still unclear. This review considers recent advances in cisplatin-induced release of EVs from tumor cells, with the expectation of providing a new understanding of the mechanisms of cisplatin treatment and drug resistance, as well as strategies for the combined use of cisplatin and other drugs.
顺铂是一种用于治疗实体瘤的一线临床药物。顺铂会损伤肿瘤细胞的 DNA，并诱导产生大量的活性氧物质，从而实现肿瘤杀伤。肿瘤细胞已经进化出几种耐受这种损伤的方式。细胞外囊泡 (EVs) 是肿瘤细胞中一种重要的信息传递方式。EVs 在顺铂处理下会被大量激活，并根据其不同的 cargo 介导肿瘤细胞在顺铂处理下的不同反应。然而，肿瘤细胞来源的 EVs 在顺铂处理下的作用机制及其潜在的 cargo 仍然不清楚。本综述考虑了顺铂诱导肿瘤细胞 EVs 释放的最新进展，期望为理解顺铂治疗和耐药的机制以及顺铂与其他药物联合使用的策略提供新的认识。
